A Phase 3 interventional study of sacubitril/valsartan and Enalapril in Heart Failure With Preserved Ejection Fraction, sponsored by Novartis Pharmaceuticals. Completed at 381 sites in 32 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing sacubitril in Heart Failure — 5 open to participants now, 5 under way, 2 of them phase 3. sacubitril · Heart Failure.
Among the 24 studies testing sacubitril in Heart Failure, this one has the largest enrollment, is one of 3 that started in 2017, is one of 7 in phase 3, and was the 4th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →5 of the 24 studies testing sacubitril in Heart Failure are open now, in 5 countries. Recruiting first, the newest first:
Martin Rohacek · Sites in Tanzania
Ages 18+
Kafrelsheikh University · Sites in Egypt
Ages 18+
John Paul II Hospital, Krakow · Sites in Poland
Ages 18+
Heart Center Research, LLC · Sites in United States
Ages 19+
Puerta de Hierro University Hospital · Sites in Spain
Ages 18+
By country, each count listing its studies:
sacubitril: first FDA approval 2015 (ENTRESTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,572 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 104 across the 24 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
74 studies in Heart Failure by Novartis: 4 open now, 4 under way, 2 of them phase 3. Of 68 finished, 38 (56%) have results posted.
Among the 74 studies in Heart Failure by Novartis, this one is the 5th largest by enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2017, is one of 21 in phase 3, and was the 42nd registered.
Novartis’s Heart Failure studies by the year they started, since 2002.
1 of the studies testing sacubitril in Heart Failure that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712030Phase 3Puerta de Hierro University HospitalEffect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing sacubitril in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 74 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).
This study was a 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate sacubitril/valsartan compared to individualized medical therapy on NT proBNP, exercise capacity, symptoms and QoL in patients with heart failure and preserved left ventricular ejection (HFpEF) fraction (LVEF > 40%). Patients were initially stratified into one of three strata according to prior treatment for comorbidities: Angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or no prior renin angiotensin system inhibitors (RASi). Patients in each stratum were randomized in a 1:1 ratio and received either sacubitril/valsartan or comparator (i.e.
enalapril for patients in ACEi strata, valsartan for patients in the ARB strata and placebo for patients in the No RASi strata). There was no designated proportion of patients planned in each stratum; the strata were populated based upon the patient's prior treatment regimen. The study consisted of a screening epoch of up to 2 weeks and a randomized treatment epoch of 24 weeks, which included a 1 to 4 week study drug up-titration epoch followed by a 20 to 23 week maintenance epoch. Uptitration to target doses was recommended to occur within the first four weeks of the study, and was performed by Investigator's discretion based on the patient's clinical status.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
This study's enrollment of 2,572 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Heart Failure, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo. Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo). In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally).
Drug: sacubitril/valsartan · Drug: Placebo to match enalapril · Drug: Placebo to match valsartan
Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum). Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily). Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily). Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo.
Drug: Enalapril · Drug: Valsartan · Drug: Placebo to match sacubitril/valsartan
Drug pages: Sacubitril · Valsartan
Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12
To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT-proBNP from baseline at Week 12 in patients with HFpEF
Time frame: Baseline, week 12
Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24
Change from baseline in 6-minute walk distance (6MWD) will be reported at Week 24. The 6 MWT will be performed in accordance with the guidelines of the American Thoracic Society 2002.
Time frame: Baseline, week 24
Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24
The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.
Time frame: Baseline, Week 24
Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24
Percentage of patients with KCCQ CSS deterioration ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.
Time frame: Baseline, Week 24
Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24
Percentage of patients with KCCQ CSS improvement ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.
Time frame: Baseline, Week 24
Change From Baseline in NYHA Functional Class at Week 24
NYHA classification is a subjective physician's assessment of patient's functional capacity and symptomatic status and can change frequently over time. Class I - No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF Class II - Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF Class III - Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF Class IV - Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest The NYHA class change will be analyzed as a three category ordinal variable with levels: "improved", "unchanged", and "worsened", defined by at least one class improvement, no change, at least one class worsening, in NYHA class, respectively.
Time frame: Baseline, week 24
Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
The SF-36 PCS score reflects the measure of quality of life based on the 36 questions which evaluate the person's physical, emotional, and mental status, including general health. Specifically, the SF-36 PCS score focuses on assessing the person's physical status. The score ranges from 0 to 100 with a higher score indicating a better status of physical wellbeing (range = 0 "worst"-100 "best").
Time frame: Baseline, Week 24
A total of 2572 participants were randomized in a 1:1 ratio to receive either sacubitril/valsartan or Individualized Medical Therapy (IMT).
| Milestone | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator |
|---|---|---|
| Started | 1286 | 1286 |
| Completed | 1235 | 1236 |
| Not completed | 51 | 50 |
| Withdrew: Physician decision | 0 | 4 |
| Withdrew: Death | 23 | 17 |
| Withdrew: Withdrawal by subject | 19 | 25 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Technical problems | 5 | 1 |
To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT-proBNP from baseline at Week 12 in patients with HFpEF
| Ratio | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator |
|---|---|---|
| Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 | 0.8218 (0.7955 to 0.8489) | 0.9828 (0.9515 to 1.0151) |
Change from baseline in 6-minute walk distance (6MWD) will be reported at Week 24. The 6 MWT will be performed in accordance with the guidelines of the American Thoracic Society 2002.
| Meters | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator |
|---|---|---|
| Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24 | 9.6935 (5.4310 to 13.9559) | 12.1920 (7.9202 to 16.4638) |
The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.
| Scores on a scale | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator |
|---|---|---|
| Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24 | 12.3399 (11.3151 to 13.3647) | 11.8168 (10.7922 to 12.8415) |
Percentage of patients with KCCQ CSS deterioration ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.
| Percentage of participants | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator |
|---|---|---|
| Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24 | 15.49 | 16.69 |
Percentage of patients with KCCQ CSS improvement ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.
| Percentage of participants | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator |
|---|---|---|
| Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24 | 67.94 | 65.70 |
NYHA classification is a subjective physician's assessment of patient's functional capacity and symptomatic status and can change frequently over time. Class I - No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF Class II - Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF Class III - Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF Class IV - Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest The NYHA class change will be analyzed as a three category ordinal variable with levels: "improved", "unchanged", and "worsened", defined by at least one class improvement, no change, at least one class worsening, in NYHA class, respectively.
| Percentage of Participants | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator |
|---|---|---|
| Improved | 23.62 | 24.00 |
| Unchanged | 72.23 | 71.68 |
| Worsened | 4.15 | 4.31 |
The SF-36 PCS score reflects the measure of quality of life based on the 36 questions which evaluate the person's physical, emotional, and mental status, including general health. Specifically, the SF-36 PCS score focuses on assessing the person's physical status. The score ranges from 0 to 100 with a higher score indicating a better status of physical wellbeing (range = 0 "worst"-100 "best").
| Scores on a scale | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator |
|---|---|---|
| Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24 | 2.5405 (2.0787 to 3.0023) | 2.6975 (2.2360 to 3.1590) |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approx. 2 years.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sacubitril/Valsartan (LCZ696) | 23/1,280 (1.8%) | 186/1,280 (14.5%) | 964/1,280 (75.3%) |
| Individualized Medical Therapy (IMT) | 17/1,284 (1.3%) | 191/1,284 (14.9%) | 832/1,284 (64.8%) |
| Total | 40/2,564 (1.6%) | 377/2,564 (14.7%) | 1,796/2,564 (70%) |
| Event | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) | Total |
|---|---|---|---|
| Cardiac failureCardiac disorders | 21/1280 | 31/1284 | 52/2564 |
| Atrial fibrillationCardiac disorders | 13/1280 | 17/1284 | 30/2564 |
| PneumoniaInfections and infestations | 13/1280 | 13/1284 | 26/2564 |
| Cardiac failure acuteCardiac disorders | 3/1280 | 9/1284 | 12/2564 |
| Angina pectorisCardiac disorders | 8/1280 | 8/1284 | 16/2564 |
| Angina unstableCardiac disorders | 6/1280 | 7/1284 | 13/2564 |
| Cardiac failure congestiveCardiac disorders | 2/1280 | 7/1284 | 9/2564 |
| Acute kidney injuryRenal and urinary disorders | 4/1280 | 7/1284 | 11/2564 |
| HypotensionVascular disorders | 6/1280 | 2/1284 | 8/2564 |
| Ischaemic strokeNervous system disorders | 0/1280 | 6/1284 | 6/2564 |
| Event | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) | Total |
|---|---|---|---|
| HypotensionVascular disorders | 176/1280 | 69/1284 | 245/2564 |
| Urine albumin/creatinine ratio increasedInvestigations | 157/1280 | 97/1284 | 254/2564 |
| Glomerular filtration rate decreasedInvestigations | 137/1280 | 150/1284 | 287/2564 |
| HyperkalaemiaMetabolism and nutrition disorders | 148/1280 | 138/1284 | 286/2564 |
| Renal impairmentRenal and urinary disorders | 148/1280 | 110/1284 | 258/2564 |
| HaematuriaRenal and urinary disorders | 145/1280 | 104/1284 | 249/2564 |
| ProteinuriaRenal and urinary disorders | 121/1280 | 84/1284 | 205/2564 |
| HypertensionVascular disorders | 42/1280 | 81/1284 | 123/2564 |
| DizzinessNervous system disorders | 70/1280 | 63/1284 | 133/2564 |
| Urine protein/creatinine ratio increasedInvestigations | 66/1280 | 65/1284 | 131/2564 |
The Full Analysis Set was the primary efficacy population used in the analyses for all efficacy endpoints and included all randomized patients except 6 patients (5 in sacubitril/valsartan group and 1 in IMT group) excluded due to misrandomization or misstratification.
| Age, Customized(Participants) | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator | Total |
|---|---|---|---|
| <65 years | 196 | 221 | 417 |
| >=65 years | 1085 | 1064 | 2149 |
| Sex: Female, Male(Participants) | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator | Total |
|---|---|---|---|
| Female | 643 | 658 | 1301 |
| Male | 638 | 627 | 1265 |
| Race/Ethnicity, Customized(Participants) | Sacubitril/Valsartan (LCZ696) | Individualized Medical Therapy (IMT) Comparator | Total |
|---|---|---|---|
| Caucasian | 1112 | 1117 | 2229 |
| Black | 11 | 16 | 27 |
| Asian | 56 | 59 | 115 |
| Native American | 39 | 33 | 72 |
| Pacific Islander | 0 | 1 | 1 |
| Unknown | 4 | 3 | 7 |
| Other | 59 | 56 | 115 |
Showing the first 100 of 381 sites across 32 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2017 to primary completion in Oct 2019, 26 months.
Results were first posted in Feb 2021, 1 year 3 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 26 months is below that.
Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sacubitril · Valsartan